Supporter Overview
Quitting smoking is the single best thing an individual can do to reduce their risk of lung cancer. In fact, after 10 years smokefree, your risk of developing lung cancer is cut in half. Of the 36.5 million current adult smokers, over 70 percent say they want to quit smoking and 40 percent will try this year. While quitting smoking can be difficult, pairing a behavioral support program—like a Freedom From Smoking® group clinic or online course —with nicotine replacement therapy can double your chances of quitting successfully.
Past and Current Projects
From October 29 through December 2, 2017, for every box of Nicorette® or NicoDerm® CQ® purchased at CVS Pharmacy, GSK Consumer Healthcare will donate $1, up to $100,000, to the American Lung Association's LUNG FORCE to raise awareness and critical funding for lung cancer research and support.
About GSK Consumer Healthcare
With over 50 years in respiratory care, GSK is committed to helping patients breathe better by continuously redefining treatment for COPD and asthma. We are driven by our commitment to research and uniting innovative science and technology to help people with these respiratory conditions live more comfortably. Equally prioritizing people and our scientific innovation, we endeavor to meet the needs of our entire patient community, so that even more patients achieve the best possible outcomes. In turn, we discover and develop new medicines and technologies that transform respiratory disease symptom management and improve overall lung health.
So long as people experience asthma and COPD exacerbations and symptoms, there is more for us to do. At GSK, our goal is to help people with respiratory conditions to not only live, but to live well.
Page last updated: September 10, 2024
